tirzepatide fda announcement May 18, 2026: warns 503B compounding pharmacy for producing after shortage ended – Partnership for Safe Medicines Lilly's Zepbound (aka tirzepatide) Lands

Medical Aesthetics News Portland, OR July 24, 2026 By Cosmetiq Medicine A clinical review published this week put a number on something injectors have been watching for three years: the facial changes that follow rapid weight loss on GLP-1 medications are now driving measurable demand for aesthetic treatment

And so they go to a shrink

Semaglutide is a medication approved by the FDA for the treatment of type 2 diabetes and, more recently, for chronic weight management in adults with obesity or overweight conditions

Once secreted into the bloodstream, GLP-1 travels to target tissues including the pancreas, brain, and stomach